I found my previous post interesting about Lilly. I think Barr is the one who will be looking. I've personally been adding to to BNT below 9. Barr successfully completed the acquisition of Women's Capital Corporation in March of this year and Duramed Pharmaceuticals in October 2001. With over 400 million in cash and a credit line available. I think Barr's ready to strike. It may not be BNT, but I can wait for someone else. I know Merck AG is still looking for more add ons.
Barr Obtains $175 Million Credit Facility
WOODCLIFF LAKE, N.J., Aug 31, 2004 /PRNewswire-FirstCall via COMTEX/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that it has established a $175 million, five-year, senior unsecured revolving credit facility. The Company expects to use the proceeds of the credit facility for working capital, capital expenditures, acquisitions and other general corporate purposes.
Snip Form Barr's 10K
Competition
As with any successful business, the greatest challenge we face is continuing to stay ahead of the competition, both for generic and proprietary products. Our successful generic product strategy has attracted new competitors seeking to launch competing generic products. For example, we know that other generic pharmaceutical companies have recently started developing and marketing competing generic oral contraceptives in order to capture some of our market share.
Also, as a challenge to the value of our patent challenge strategy, brand pharmaceutical companies have begun to partner with certain generic drug companies to license a so-called "authorized generic" to the generic drug company.
--------------------------------------------------------------------------------
Table of Contents
The use of authorized generics by certain brand and generic companies undermines the value of the 180 day exclusivity period enjoyed by the first company to file an ANDA containing a Paragraph IV certification by providing another generic drug company with the ability to have the product on the market at the same time.
Finally, as our proprietary pharmaceutical products grow, we anticipate that competing generic pharmaceutical companies will challenge the patents protecting our branded products. For example, our SEASONALE extended cycle oral contraceptive product was recently targeted for a patent challenge by one of our principal competitors.
To address these and other challenges, we continue to (1) invest aggressively in research and development, (2) develop and launch new generic and proprietary products and (3) maintain an active acquisition and licensing effort to complement our internal development activities.
Comparison of the fiscal years ended June 30, 2004 and June 30, 2003
($'s in millions)
The following table sets forth revenue data for the fiscal years ended June 30, 2004 and 2003: |
